Trial reportDrug and alcohol dependence2013
The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study.
Trial report in Drug and alcohol dependence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis.JAMA network open · 2021Pooled it
- Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.Journal of general internal medicine · 2019Pooled it
- Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin.Addiction biology · 2019Trial
- Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.The American journal of psychiatry · 2018Trial
- A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco-deprived and -satiated smokers.Human psychopharmacology · 2018Trial
- Carvedilol does not reduce cocaine use in methadone-maintained cocaine users.Journal of substance abuse treatment · 2017Trial
- Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.Addiction biology · 2016Trial
- Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.Progress in neuro-psychopharmacology & biological psychiatry · 2015Trial
- Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2013Trial
- The Role of the Ventral Tegmental Area in Reward and Addiction: A Comprehensive Review.Neurosciences (Riyadh, Saudi Arabia) · 2026Review
- Novel neurotherapeutic targets for substance use disorders: Neuroplasticity, neuroinflammation, gasotransmitters and non-canonical organ systems.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Doxazosin for the treatment of mental health disorders: A scoping review.PLOS mental health · 2025Article
- Stress and substance use disorders: risk, relapse, and treatment outcomes.The Journal of clinical investigation · 2024Review
- Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders.Journal of medicinal chemistry · 2024Article
- Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects.Cardiovascular research · 2023Review
- Noradrenergic circuits and signaling in substance use disorders.Neuropharmacology · 2022Review
- Closing the brain-heart loop: Towards more holistic models of addiction and addiction recovery.Addiction biology · 2022Review
- Regulation of cocaine seeking behavior by locus coeruleus noradrenergic activity in the ventral tegmental area is time- and contingency-dependent.Frontiers in neuroscience · 2022Article
- SUBSTANCE USE AND ADDICTION AFFECT MORE THAN THE BRAIN: THE PROMISE OF NEUROCARDIAC INTERVENTIONS.Current addiction reports · 2021Article
- Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?Addiction (Abingdon, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMedications decreasing central noradrenergic activity have been associated with attenuation of cocaine effects.
aimsThis pilot study examined the efficacy of doxazosin versus placebo for reducing cocaine use in treatment-seeking cocaine dependent persons.
methodsWe screened 108 cocaine dependent subjects and assigned 35 participants to receive either doxazosin (8mg/day) or placebo for 13 weeks. Participants were titrated on the study medication according to two different schedules. During the initial phase of the study, patients were titrated onto the study medication over an 8-week period (DOX-slow). After reviewing data from our human laboratory study, a second phase was initiated, wherein titration was accelerated to a 4-week period (DOX-fast). All participants received weekly cognitive behavioral therapy. Urine toxicology was performed thrice weekly.
resultsBaseline subject characteristics were comparable. Thirty subjects entered the study: 8 subjects in DOX-slow, 9 subjects in DOX-fast, and 13 subjects in placebo. Total number of cocaine-negative urines was significantly increased in the DOX-fast group; and percentage of total cocaine-negative urines by group were 10% for DOX-slow group, 35% for DOX-fast group, and 14% for placebo (χ(2)=36.3, df=2, p<0.0001). The percentage of participants achieving two or more consecutive weeks of abstinence by group was 0% for DOX-slow group, 44% for DOX-fast group, and 7% for placebo (χ(2)=7.35, df=2, p<0.023).
conclusionsThis pilot study suggests the potential efficacy of doxazosin when rapidly titrated in reducing cocaine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.